Nexgel Revenue Jumps 100% in Fiscal Q2

Nexgel (NASDAQ:NXGL), a maker of hydrogel-based wound care and beauty products, released its second quarter results for fiscal 2025 on August 12, 2025. The key news from the release was strong year-over-year growth in both revenue and profit margins, though results fell short of analyst estimates on both sales (GAAP revenue of $2.88 million vs. $3.08 million estimate) and earnings (non-GAAP EPS of -0.42 vs. -0.07 estimate). The company reported $2.88 million in GAAP revenue, up 100.3% from the prior year but missing the $3.08 million GAAP average forecast. Gross margin (GAAP) improved to 43.6% from 20.3% in Q2 2024. However, it recorded a GAAP net loss of $0.09 per share and a Non-GAAP adjusted EBITDA loss of $0.42 million. Management reaffirmed its yearly targets for $13 million in revenue and positive EBITDA, though achieving these will require acceleration in the second half. Overall, the period showed progress in business diversification and margin improvement, but ongoing net losses (GAAP) and slow sequential revenue growth ($2.88 million, up from $2.81 million in Q1 2025) pose challenges ahead. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Nexgel produces hydrogel-based products for both the medical and beauty markets. Its business includes contract manufacturing for external brands and the sale of its own consumer brands, such as Kenkoderm (for psoriasis relief), Medagel (wound care), and Silly George (beauty accessories). The company's core technology uses electron-beam cross-linking for hydrogels, providing a skin-friendly, high-water content material suitable for medical and cosmetic uses.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool